First-in-human single-dose study of nizubaglustat, a dual inhibitor of ceramide glucosyltransferase and non-lysosomal glucosylceramidase: Safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending and multiple doses in healthy adults
-
Published:2024-01
Issue:1
Volume:141
Page:108113
-
ISSN:1096-7192
-
Container-title:Molecular Genetics and Metabolism
-
language:en
-
Short-container-title:Molecular Genetics and Metabolism
Author:
Paquet Luzy Cecile,Doppler Emilie,Polasek Thomas M.,Giorgino Ruben
Subject
Endocrinology,Genetics,Molecular Biology,Biochemistry,Endocrinology, Diabetes and Metabolism
Reference83 articles.
1. Lysosomal storage diseases;Platt;Nat. Rev. Dis. Prim.,2018
2. Lysosomal storage diseases;Ferreira,2017
3. Inborn errors of metabolism;Ferreira;Handb. Clin. Neurol.,2019
4. Mass spectrometry-based proteomics in neurodegenerative lysosomal storage disorders;Li;Mol. Omics.,2022
5. Inherited disorders of lysosomal membrane transporters;Huizing;Biochim. Biophys. Acta Biomembr.,2020